查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1540801

2024-2032 年按分析技术、生物分子、癌症类型、应用、最终用户和地区分類的癌症生物标记市场报告

Cancer Biomarkers Market Report by Profiling Technology, Biomolecule, Cancer Type, Application, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球癌症生物标记市场规模达279亿美元。个人化医疗的进步，基因组学、蛋白质组学和生物资讯学等技术的重大创新，对伴随诊断的需求增加以及人口老化的加剧是推动市场的一些主要因素。

癌症生物标记是可以在体内发现的特定分子或物质，并提供有关癌症的存在、进展或特征的有价值的资讯。这些生物标记在肿瘤学领域中发挥着至关重要的作用，有助于各种癌症的早期检测、诊断、治疗监测和预后。它们通常存在于血液、尿液、组织或其他体液中。癌症生物标记的鑑定和分析涉及基因组学、蛋白质组学和代谢组学等先进技术。这些技术使研究人员和医疗保健专业人员能够检测分子层面的细微变化，从而深入了解癌症的发展及其对治疗的反应。透过测量特定生物标记的水平，临床医生可以为个别患者量身定制治疗计划，从而实现更有针对性的治疗并改善结果。

全球各种癌症盛行率的不断上升是一个重要的驱动因素。随着癌症病例数量的增加，对生物标记等准确的早期诊断工具的需求不断增加。此外，生物标记提供非侵入性的癌症检测和监测方法，减少患者不适并实现频繁评估。这种便利性推动了患者的接受度和临床采用。除此之外，早期发现对于提高存活率至关重要。癌症生物标记可以在癌症的最早阶段进行检测，从而实现及时干预和潜在的治癒性治疗。除此之外，对伴随诊断的需求正在促进生物标记市场的成长，伴随诊断有助于确定对患者最有效的治疗方法。与此一致的是，全球老化人口更容易罹患癌症。这种人口趋势推动了对改进诊断和治疗方法的需求，其中生物标记发挥关键作用。此外，基因组学、蛋白质组学和生物资讯学等技术的快速进步彻底改变了癌症生物标记的发现和分析。这些技术能够以更高的灵敏度和特异性鑑定新型生物标记。此外，向个人化医疗的转变增加了对生物标记的需求，因为它们能够识别每个患者癌症特有的特定遗传、分子和蛋白质组特征，促进标靶治疗并改善治疗结果。

癌症生物标记市场趋势/驱动因素：

全球癌症盛行率不断上升，为市场创造了积极的前景。生物标记广泛用于早期癌症检测以及治疗和管理过程中，以准确可靠地预测结果。与此一致的是，由于污染水平上升、吸烟趋势和不良饮食习惯导致肺癌发病率不断增加，从而促进了市场的成长。此外，遗传生物标记发现的各种技术进步，例如次世代定序（NGS）、聚合酶炼式反应（PCR）、基因表现谱（微阵列）和人工不雅（AI）有助于预测癌症復发后的復发。此外，医疗保健专业人员和患者对早期诊断重要性的认识不断提高，以及由于缺乏标准诊断而导致癌症治疗向个人化医疗的重大转变，有利于市场成长。其他因素，包括医疗保健行业的显着增长、广泛的研发 (R&D) 活动以及加强药物开发流程的各种政府倡议的实施，预计将推动市场成长。

癌症发生率上升

世界卫生组织 (WHO) 报告称，由于生活方式改变、环境暴露和人口老化等因素，癌症病例负担不断增加。这种激增需要改进诊断工具，以便在治疗最有效的最早期阶段检测出癌症。癌症生物标记能够识别细微的分子变化，从而实现早期检测和风险评估。这使得医疗保健专业人员能够制定量身定制的治疗计划，优化患者的治疗结果。随着癌症盛行率持续上升，对生物标记等准确、高效的诊断解决方案的需求预计将保持上升趋势。

个人化医疗的进步

每种癌症都是独特的，由独特的遗传和分子特征驱动。这种复杂性需要量身定制的治疗方法来解决个别癌症的特定属性。生物标记为了解这些错综复杂的问题提供了一个窗口，使临床医生能够选择针对驱动疾病的精确分子改变的疗法。透过最大限度地减少治疗选择中的反覆试验，个人化医疗可以提高治疗效果，同时减少不良反应。由于可以快速分析患者遗传和分子特征的先进技术的出现，这种方法受到了关注。随着个人化医疗日益受到重视，对指导治疗决策的生物标记的需求将持续增长。

重大技术创新

新一代定序、质谱和微阵列分析等高通量技术的出现大大提高了我们识别和分析潜在生物标记的能力。这些方法能够辨识出指示不同癌症类型的特定基因突变、表观遗传学变化和蛋白质表现模式。此外，生物资讯学工具有助于解释大量资料集，有助于发现新的候选生物标记。这些技术进步不仅加快了生物标记的发现，还提高了其敏感性和特异性，使它们在临床使用中更加可靠。随着技术的不断发展，预计经过验证的癌症生物标记库将会扩大，进一步塑造癌症诊断和治疗的模式。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球癌症生物标记市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：透过分析技术

  • 欧米克科技
    • 市场趋势
    • 市场预测
  • 影像技术
    • 市场趋势
    • 市场预测
  • 免疫测定
    • 市场趋势
    • 市场预测
  • 细胞遗传学
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依生物分子

  • 基因生物标记
    • 市场趋势
    • 市场预测
  • 蛋白质生物标记
    • 市场趋势
    • 市场预测
  • 糖生物标记
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按癌症类型

  • 乳癌
    • 市场趋势
    • 市场预测
  • 肺癌
    • 市场趋势
    • 市场预测
  • 大肠直肠癌
    • 市场趋势
    • 市场预测
  • 摄护腺癌
    • 市场趋势
    • 市场预测
  • 胃癌
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按应用

  • 诊断
    • 市场趋势
    • 市场预测
  • 预测
    • 市场趋势
    • 市场预测
  • 风险评估
    • 市场趋势
    • 市场预测
  • 药物发现与开发
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：依最终用户

  • 医院
    • 市场趋势
    • 市场预测
  • 学术研究机构
    • 市场趋势
    • 市场预测
  • 门诊手术中心
    • 市场趋势
    • 市场预测
  • 诊断实验室
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 11 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 12 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 13 章：价值链分析

第 14 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 15 章：价格分析

第16章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • Becton Dickinson and Company
    • bioMerieux SA
    • Danaher Corporation
    • F. Hoffmann-La Roche AG
    • General Electric Company
    • Illumina Inc.
    • Qiagen NV
    • Sino Biological Inc.
    • Thermo Fisher Scientific Inc.
Product Code: SR112024A5834

The global cancer biomarkers market size reached US$ 27.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 77.0 Billion by 2032, exhibiting a growth rate (CAGR) of 11.7% during 2024-2032.The rising cancer incidences, advancements in personalized medicine, significant innovations in technologies such as genomics, proteomics, and bioinformatics, augmenting demand for companion diagnostics, and increasing aging population some of the major factors propelling the market.

Cancer biomarkers are specific molecules or substances that can be found in the body and provide valuable information about the presence, progression, or characteristics of cancer. These biomarkers play a crucial role in the field of oncology by aiding in the early detection, diagnosis, treatment monitoring, and prognosis of various types of cancer. They are typically present in blood, urine, tissues, or other bodily fluids. The identification and analysis of cancer biomarkers involve advanced techniques such as genomics, proteomics, and metabolomics. These techniques enable researchers and healthcare professionals to detect subtle changes at the molecular level, which can provide insights into the development of cancer and its response to treatments. By measuring the levels of specific biomarkers, clinicians can tailor treatment plans to individual patients, leading to more targeted therapies and improved outcomes.

The increasing prevalence of various types of cancers across the globe is a significant driver. As the number of cancer cases grows, the demand for accurate and early diagnostic tools, like biomarkers, intensifies. Additionally, biomarkers offer non-invasive methods of cancer detection and monitoring, reducing patient discomfort and enabling frequent assessments. This convenience is driving both patient acceptance and clinical adoption. Other than this, early detection is crucial for improving survival rates. Cancer biomarkers allow for the detection of cancers at their earliest stages, enabling timely intervention and potentially curative treatments. Besides this, the demand for companion diagnostics, which help determine the most effective treatment for a patient, is fostering the growth of the biomarkers market. In line with this, the global aging population is more susceptible to cancer. This demographic trend is driving the need for improved diagnostic and therapeutic approaches, in which biomarkers play a pivotal role. Furthermore, rapid advancements in technologies such as genomics, proteomics, and bioinformatics have revolutionized cancer biomarker discovery and analysis. These technologies enable the identification of novel biomarkers with higher sensitivity and specificity. Moreover, the shift toward personalized medicine has escalated the demand for biomarkers as they enable the identification of specific genetic, molecular, and proteomic signatures unique to each patient's cancer, facilitating targeted therapies and improving treatment outcomes.

Cancer Biomarkers Market Trends/Drivers:

The increasing prevalence of cancer across the globe is creating a positive outlook for the market. Biomarkers are widely used for early cancer detection and during treatment and management to accurately and reliably predict outcomes. In line with this, the increasing incidences of lung cancer due to the upsurge in pollution levels, smoking trends and poor ingestion habits is augmenting the market growth. Moreover, various technological advancements in genetic biomarker discovery, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), gene expression profiling (microarray), and the artificial inelegance (AI) that assist in predicting the recurrence of cancer after treatment, are providing an impetus to the market growth. Additionally, the increasing awareness amongst healthcare professionals and patients about the importance of early diagnosis and the significant shift toward personalized medicine for cancer treatment due to the lack of standard diagnosis is favoring the market growth. Other factors, including the significant growth in the healthcare industry, extensive research and development (R&D) activities and the implementation of various government initiatives for enhancing the drug development processes, are anticipated to drive the market toward growth.

Rising Cancer Incidence

The World Health Organization (WHO) reports a growing burden of cancer cases, attributed to factors such as lifestyle changes, environmental exposures, and an aging population. This surge necessitates improved diagnostic tools that can detect cancer at its earliest stages, when treatment is most effective. Cancer biomarkers, with their ability to identify subtle molecular changes, enable early detection and risk assessment. This empowers healthcare professionals to devise tailored treatment plans, optimizing patient outcomes. As cancer prevalence continues to escalate, the demand for accurate and efficient diagnostic solutions like biomarkers is expected to remain on an upward trajectory.

Advancements in Personalized Medicine

Each cancer is unique, driven by distinct genetic and molecular characteristics. This complexity demands tailored treatment approaches that address the specific attributes of an individual's cancer. Biomarkers offer a window into these intricacies, allowing clinicians to select therapies that target the precise molecular alterations driving the disease. By minimizing trial and error in treatment selection, personalized medicine enhances treatment efficacy while reducing adverse effects. This approach has gained traction due to the availability of advanced technologies that can rapidly analyze a patient's genetic and molecular profile. As personalized medicine gains prominence, the demand for biomarkers that guide treatment decisions will continue to grow.

Significant Technological Innovations

The advent of high-throughput techniques such as next-generation sequencing, mass spectrometry, and microarray analysis has exponentially increased our ability to identify and analyze potential biomarkers. These methods enable the identification of specific genetic mutations, epigenetic changes, and protein expression patterns that are indicative of different cancer types. Moreover, bioinformatics tools facilitate the interpretation of vast datasets, aiding in the discovery of novel biomarker candidates. These technological advancements not only expedite biomarker discovery but also enhance their sensitivity and specificity, making them more reliable for clinical use. As technology continues to evolve, it is anticipated that the pool of validated cancer biomarkers will expand, further shaping the landscape of cancer diagnosis and treatment.

Cancer Biomarkers Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global cancer biomarkers market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on profiling technology, biomolecule, cancer type, application, and end user.

Breakup by Profiling Technology:

Omic Technologies

Imaging Technologies

Immunoassays

Cytogenetics

The report has provided a detailed breakup and analysis of the market based on the profiling technology. This includes omic technologies, imaging technologies, immunoassays, and cytogenetics.

Omic technologies, encompassing genomics, proteomics, and metabolomics, play a pivotal role in cancer biomarker discovery and profiling. Genomic analysis reveals alterations in DNA sequences, identifying mutations and genetic variations associated with cancer development. Proteomics delves into the intricate world of proteins, identifying biomarkers by studying their expression levels, modifications, and interactions. Metabolomics focuses on small molecule metabolites, shedding light on metabolic pathways disrupted in cancer. These omic approaches provide a comprehensive understanding of the molecular intricacies underlying cancer, enabling the identification of potential biomarkers with high precision. Their ability to uncover subtle changes in genes, proteins, and metabolites makes omic technologies indispensable in the quest for reliable cancer biomarkers, enhancing diagnostic accuracy and paving the way for targeted therapies.

Techniques like positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT) provide detailed anatomical and functional information. These technologies enable the visualization of tumors, their growth patterns, and interactions with surrounding tissues. Molecular imaging techniques, a subset of imaging technologies, utilize specific tracers to visualize molecular changes within tumors. This aids in identifying unique biomarkers expressed on cancer cells. Imaging-based biomarker profiling not only aids in accurate diagnosis but also assists in treatment planning and monitoring. As imaging technologies continue to advance, their role in non-invasive biomarker identification and real-time monitoring of treatment responses becomes increasingly integral.

Enzyme-linked immunosorbent assays (ELISA) and multiplex immunoassays measure the concentration of specific proteins, including biomarkers indicative of various cancers. Their high sensitivity and ability to analyze multiple analytes simultaneously make immunoassays invaluable in cancer diagnosis, prognosis, and therapeutic monitoring. Immunoassays are particularly well-suited for measuring soluble proteins and antigens present in blood or other bodily fluids. The advent of novel immunoassay platforms, such as bead-based and microfluidic systems, further enhances their capabilities. Immunoassay-based biomarker profiling not only aids in clinical decision-making but also expedites the development of targeted therapies by identifying patients likely to respond favorably to specific treatments.

Breakup by Biomolecule:

Genetic Biomarkers

Protein Biomarkers

Glyco-Biomarkers

Genetic biomarkers hold the largest share in the market

A detailed breakup and analysis of the market based on the biomolecule has also been provided in the report. This includes genetic biomarkers, protein biomarkers, and glycol-biomarkers. According to the report, genetic biomarkers accounted for the largest market share.

Genetic biomarkers offer insights into an individual's genetic predisposition, mutations, and variations that contribute to disease development. The advent of advanced genomic sequencing technologies has revolutionized our ability to decode the genetic code, identifying specific gene alterations associated with various cancers. Genetic biomarkers not only facilitate early cancer detection but also guide personalized treatment strategies. By pinpointing genetic mutations driving a particular cancer, clinicians can tailor therapies to target these specific genetic anomalies, thereby enhancing treatment efficacy while minimizing adverse effects. Moreover, genetic biomarkers play a crucial role in the development of precision medicine, where treatments are tailored to a patient's genetic profile.

Breakup by Cancer Type:

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Stomach Cancer

Others

Lung cancer dominates the market

The report has provided a detailed breakup and analysis of the market based on the cancer type. This includes breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, and others. According to the report, lung cancer represented the largest segment.

Lung cancer holds a significant global prevalence, ranking among the leading causes of cancer-related deaths. The strong association between lung cancer and smoking, along with environmental factors, contributes to its widespread occurrence. Furthermore, advancements in diagnostic technologies, including imaging and molecular profiling, have improved lung cancer detection and classification. This has led to a higher number of diagnosed cases, contributing to the segment's prominence. Additionally, the complex nature of lung cancer, characterized by diverse subtypes like non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), necessitates targeted therapies based on biomarker profiles. This drives research and innovation, fostering the development of precision medicine approaches tailored to specific lung cancer subtypes.

Breakup by Application:

Diagnostics

Prognostics

Risk Assessment

Drug Discovery and Development

Others

A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes diagnostics, prognostics, risk assessment, drug discovery and development, and others.

Cancer biomarkers play a critical role in enabling early and accurate cancer detection. By identifying specific molecular signatures associated with various cancer types, biomarkers assist in pinpointing the presence of cancer at its initial stages. This facilitates timely intervention, ultimately leading to improved patient outcomes. Biomarker-based diagnostics encompass a range of techniques, including blood tests, imaging, and molecular assays, which collectively contribute to effective and non-invasive cancer detection.

By analyzing specific biomarkers, clinicians can gauge the aggressiveness of the cancer, assess the risk of recurrence, and estimate patient survival rates. These insights guide treatment planning, allowing for tailored therapies that match the anticipated disease trajectory. Prognostic biomarkers contribute to informed decision-making, enabling patients and healthcare providers to make choices aligned with individual prognosis.

These biomarkers enable early screening of individuals at elevated risk due to genetic, environmental, or lifestyle factors. By identifying those at risk, healthcare professionals can implement targeted surveillance, preventive measures, and lifestyle interventions to reduce the likelihood of cancer development. Risk management based on biomarkers empowers proactive healthcare strategies that emphasize prevention and early intervention.

Breakup by End User:

Hospitals

Academic and Research Institutions

Ambulatory Surgical Centers

Diagnostic Laboratories

Others

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, academic and research institutions, ambulatory surgical centers, diagnostic laboratories, and others.

With their comprehensive range of medical services and infrastructure, hospitals serve as essential hubs for cancer diagnosis, treatment, and management. Biomarker-based tests are seamlessly integrated into hospital workflows, facilitating timely and accurate cancer diagnosis. Hospitals also offer the necessary facilities for patient monitoring and follow-up, making them central to cancer care. The demand for biomarkers in hospitals is driven by the need for efficient diagnostic tools that aid in early detection, prognosis, and treatment decision-making.

These institutions conduct in-depth research to identify and validate novel biomarkers, contributing to the expansion of our understanding of cancer biology. They also develop cutting-edge technologies and methodologies for biomarker discovery and analysis. Academic institutions serve as platforms for training the next generation of researchers, clinicians, and professionals who will drive biomarker-related research and applications. Additionally, academic collaborations often lead to the development of innovative diagnostic and therapeutic approaches, further enriching the biomarkers market.

These centers provide outpatient surgical and medical procedures, including cancer diagnostics and treatment. ASCs offer efficient and convenient options for patients who require biomarker-based tests, minimizing the need for hospitalization. They cater to patients seeking specialized care in a more streamlined and patient-centered environment. As the trend towards outpatient care continues to grow, ambulatory surgical centers are increasingly adopting biomarker-based diagnostic and treatment methods, contributing to their significance within the market ecosystem.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for cancer biomarkers.

North America possesses a well-established healthcare infrastructure with advanced medical facilities, research centers, and academic institutions. This provides a conducive environment for the integration of biomarker-based diagnostics and treatments into clinical practice. Additionally, substantial investments in cancer research and healthcare technology contribute to the continuous advancement of biomarker discovery and validation. This, coupled with a strong emphasis on personalized medicine, drives the demand for biomarker-driven approaches in patient care. Moreover, North America's proactive regulatory landscape, with agencies like the FDA, fosters the validation and approval of new biomarkers, ensuring their safety and efficacy. This regulatory support instills confidence among healthcare professionals and encourages the adoption of biomarker-based tests. Besides this, a higher awareness of cancer prevention, early detection, and treatment options within the population further fuels the demand for biomarker-based solutions. The presence of a substantial patient pool and a robust pharmaceutical industry also play a pivotal role in the region's dominance in the cancer biomarkers market.

Competitive Landscape:

Major players invest heavily in R&D to identify and validate new biomarkers. This involves extensive laboratory research, clinical trials, and collaborations with academic institutions to discover biomarkers that offer higher accuracy and specificity in cancer detection and monitoring. Additionally, collaboration between biotechnology firms, pharmaceutical companies, research institutions, and healthcare providers accelerates the translation of biomarker discoveries into practical applications. Partnerships facilitate the development of novel diagnostics and therapies that incorporate biomarker information. Other than this, key players continually innovate by adopting and developing cutting-edge technologies, such as next-generation sequencing, liquid biopsies, and advanced imaging techniques. These innovations enhance biomarker detection sensitivity, allowing for earlier and more accurate cancer diagnoses. Besides this, leading firms are focusing on developing companion diagnostics that identify patients most likely to respond to specific treatments. This approach optimizes treatment selection, leading to better patient outcomes and reduced healthcare costs. In line with this, key market players are driving the shift toward personalized medicine by utilizing biomarker information to tailor treatments to individual patients. This approach improves treatment efficacy and minimizes adverse effects. Furthermore, collaboration with regulatory authorities, such as the FDA, ensures that biomarker-based tests meet rigorous standards for accuracy and safety. Regulatory approvals enhance trust in these tests among healthcare professionals and patients.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

Agilent Technologies Inc.

Becton Dickinson and Company

bioMerieux SA

Danaher Corporation

F. Hoffmann-La Roche AG

General Electric Company

Illumina Inc.

Qiagen N.V.

Sino Biological Inc.

Thermo Fisher Scientific Inc.

Recent Developments:

Thermos Fisher Scientific Inc. has recently entered into a significant companion diagnostic agreement with Chugai Pharmaceutical Co. Ltd. This collaboration holds strategic importance within the pharmaceutical and diagnostic sectors. Through this agreement, both companies aim to combine their expertise to enhance the development and availability of companion diagnostics. Thermo Fisher's prowess in cutting-edge scientific solutions and Chugai Pharmaceutical's extensive experience in pharmaceuticals complement each other, fostering the creation of advanced diagnostic tools.

Agilent Technologies Inc. introduced a noteworthy initiative in the form of a Biomarker Pathologist Training Program. This program is a significant step in the field of pathology and biomarker research. Through this endeavor, Agilent is taking a leadership role in promoting education and skill development within the domain of biomarker analysis.

Illumina Inc. embarked on a significant collaborative endeavor by forming a co-development partnership with SomaLogic. This partnership represents a pivotal moment in the landscape of biomarker research and clinical advancements. Illumina, renowned for its pioneering work in next-generation sequencing (NGS), has joined forces with SomaLogic, a distinguished name in the realm of protein biomarker discovery.

Key Questions Answered in This Report

  • 1. What was the size of the global cancer biomarkers market in 2023?
  • 2. What is the expected growth rate of the global cancer biomarkers market during 2024-2032?
  • 3. What are the key factors driving the global cancer biomarkers market?
  • 4. What has been the impact of COVID-19 on the global cancer biomarkers market?
  • 5. What is the breakup of the global cancer biomarkers market based on the biomolecule?
  • 6. What is the breakup of the global cancer biomarkers market based on the cancer type?
  • 7. What are the key regions in the global cancer biomarkers market?
  • 8. Who are the key players/companies in the global cancer biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Biomarkers Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Profiling Technology

  • 6.1 Omic Technologies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Imaging Technologies
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Immunoassays
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Cytogenetics
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Biomolecule

  • 7.1 Genetic Biomarkers
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Protein Biomarkers
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Glyco-Biomarkers
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Cancer Type

  • 8.1 Breast Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Lung Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Colorectal Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Prostate Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Stomach Cancer
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Diagnostics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Prognostics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Risk Assessment
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Drug Discovery and Development
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Academic and Research Institutions
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Ambulatory Surgical Centers
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Diagnostic Laboratories
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Others
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Abbott Laboratories
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Agilent Technologies Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Becton Dickinson and Company
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 bioMerieux SA
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Danaher Corporation
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 F. Hoffmann-La Roche AG
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 SWOT Analysis
    • 16.3.7 General Electric Company
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Illumina Inc.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Qiagen N.V.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Sino Biological Inc.
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
    • 16.3.11 Thermo Fisher Scientific Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer Biomarkers Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Biomarkers Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Cancer Biomarkers Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Cancer Biomarkers Market: Breakup by Profiling Technology (in %), 2023
  • Figure 5: Global: Cancer Biomarkers Market: Breakup by Biomolecule (in %), 2023
  • Figure 6: Global: Cancer Biomarkers Market: Breakup by Cancer Type (in %), 2023
  • Figure 7: Global: Cancer Biomarkers Market: Breakup by Application (in %), 2023
  • Figure 8: Global: Cancer Biomarkers Market: Breakup by End User (in %), 2023
  • Figure 9: Global: Cancer Biomarkers Market: Breakup by Region (in %), 2023
  • Figure 10: Global: Cancer Biomarkers (Omic Technologies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Cancer Biomarkers (Omic Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Cancer Biomarkers (Imaging Technologies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Cancer Biomarkers (Imaging Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Cancer Biomarkers (Immunoassays) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Cancer Biomarkers (Immunoassays) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Cancer Biomarkers (Cytogenetics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Cancer Biomarkers (Cytogenetics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Cancer Biomarkers (Genetic Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Cancer Biomarkers (Genetic Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Cancer Biomarkers (Protein Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Cancer Biomarkers (Protein Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Cancer Biomarkers (Glyco-Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Cancer Biomarkers (Glyco-Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Cancer Biomarkers (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Cancer Biomarkers (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Cancer Biomarkers (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Cancer Biomarkers (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Cancer Biomarkers (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Cancer Biomarkers (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Cancer Biomarkers (Prostate Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Cancer Biomarkers (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Cancer Biomarkers (Stomach Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Cancer Biomarkers (Stomach Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Cancer Biomarkers (Other Cancer Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Cancer Biomarkers (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Cancer Biomarkers (Diagnostics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Cancer Biomarkers (Diagnostics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Cancer Biomarkers (Prognostics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Cancer Biomarkers (Prognostics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: Cancer Biomarkers (Risk Assessment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: Cancer Biomarkers (Risk Assessment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Global: Cancer Biomarkers (Drug Discovery and Development) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Global: Cancer Biomarkers (Drug Discovery and Development) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Global: Cancer Biomarkers (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Global: Cancer Biomarkers (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Global: Cancer Biomarkers (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Global: Cancer Biomarkers (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Global: Cancer Biomarkers (Academic and Research Institutions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Global: Cancer Biomarkers (Academic and Research Institutions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Global: Cancer Biomarkers (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Global: Cancer Biomarkers (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Global: Cancer Biomarkers (Diagnostic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Global: Cancer Biomarkers (Diagnostic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Global: Cancer Biomarkers (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Global: Cancer Biomarkers (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: North America: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: North America: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United States: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United States: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Canada: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Canada: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Asia-Pacific: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Asia-Pacific: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: China: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: China: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Japan: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Japan: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: India: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: India: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: South Korea: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: South Korea: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Australia: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Australia: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Indonesia: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Indonesia: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Europe: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Europe: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Germany: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Germany: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: France: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: France: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: United Kingdom: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: United Kingdom: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Italy: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Italy: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Spain: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Spain: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Russia: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Russia: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Others: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 93: Others: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 94: Latin America: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 95: Latin America: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 96: Brazil: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 97: Brazil: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 98: Mexico: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 99: Mexico: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 100: Others: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 101: Others: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 102: Middle East and Africa: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 103: Middle East and Africa: Cancer Biomarkers Market: Breakup by Country (in %), 2023
  • Figure 104: Middle East and Africa: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 105: Global: Cancer Biomarkers Industry: SWOT Analysis
  • Figure 106: Global: Cancer Biomarkers Industry: Value Chain Analysis
  • Figure 107: Global: Cancer Biomarkers Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Biomarkers Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Cancer Biomarkers Market Forecast: Breakup by Profiling Technology (in Million US$), 2024-2032
  • Table 3: Global: Cancer Biomarkers Market Forecast: Breakup by Biomolecule (in Million US$), 2024-2032
  • Table 4: Global: Cancer Biomarkers Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
  • Table 5: Global: Cancer Biomarkers Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 6: Global: Cancer Biomarkers Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 7: Global: Cancer Biomarkers Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: Cancer Biomarkers Market: Competitive Structure
  • Table 9: Global: Cancer Biomarkers Market: Key Players